ON JUNE 1, 2020, Biocare Lifesciences Inc. and Beximco Pharma Ltd. have signed a marketing authorization agreement to supply the generic version of Remdesivir (Bemsivir) in the Philippines.
Beximco, a leading generic drug manufacturer in Bangladesh, is always committed in providing the latest, evidence-based treatment options to patients, as well as access to affordable medicines. The company’s state-of-the-art manufacturing facilities are accredited by the U.S. Food and Drug Administration (FDA), the Therapeutic Goods Administration Australia, the European Union, FDA Taiwan, FDA Philippines and other prestigious health regulatory authorities across the world.
Beximco is the first company in the world to launch a generic version of Remdesivir for the treatment of Covid-19. Remdesivir was originally developed by Gilead Sciences Inc. Its patent gives the U.S. company exclusive rights to make the antiviral drug, but international trade rules allow nations defined by the United Nations as least-developed countries (LDCs) to ignore the patent and make drugs such as Remdesivir more affordable in their markets.
After grabbing headlines globally in May for being the first company to market Remdesivir, this antiviral drug that has shown promising results in treating Covid-19 patients proven by various clinical studies, Beximco is now set to export the medicine to more than 30 countries.
Biocare Lifesciences Inc., a Philippine-based pharmaceutical company engaged in the business of distribution, importation and marketing of various medicines will bring the first generic brand of Remdesivir (Bemsivir) in the country.
“We are very excited and honored to work with Beximco,” said, Dileep K. Tiwari, managing director of Biocare Lifesciences Inc. “This partnership with Beximco to provide Remdesivir in the country is an exciting development for our company, and will enable us to bring a promising and affordable medicine for Covid-19 treatment.”
Biocare and Beximco are committed to fight this pandemic in all possible ways by employing the latter’s competitive research and development and manufacturing skills. Remdesivir (BEMSIVIR) will be available in hospitals to fight against Covid-19 through a Compassionate Special Permit (CSP).
Medical doctors in Philippines have also recommended the use of Remdesivir for the treatment of Covid-19. The first two hospitals to receive this product are Chong Hua Hospital and the University of Cebu Medical Center.
For more information about Biocare Lifesciences Inc., visit its website (www.BiocareLifesciencesInc.com) and Facebook page (Biocare Lifesciences Inc.). (Sponsored Content)